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Abstract
The accumulating failures in HIV vaccine development demonstrate that the immunization
approaches used so far are insufficient to reproduce the naturally occurring immunity that controls
the virus in long-term non-progressors, HIV controllers, and continuously exposed sex workers.
They also underscore the desperate need for new approaches in the design of more effective
vaccination protocols. Recent findings might have brought us closer to that goal by providing proof of
concept for a novel preventative HIV vaccine by establishing CD8 effector memory T cells within the
mucosal sites of transmission.
Introduction and context
When HIV was first discovered in 1983 [1,2], the race was
on to develop an effective vaccine. Twenty-six years later,
despite enormous efforts, we have still not reached the
finish line. The recent failure of the STEP phase 2b clinical
vaccination trial [3,4] using relatively innocuous adeno-
virus serotype 5 (Ad-5) vectors containing HIV T cell
epitopeshascausedmanytoquestiontheabilityofcellular
immunity to contribute to an effective HIV vaccine.
Retroviruses that cause AIDS in primates, including HIV
and its close relative, the simian immunodeficiency virus
(SIV), belong to the family of lentiviruses (or ‘slow’
viruses). They are known for inducing clinical disease
only after a prolonged period of relatively stable chronic
infection, during which time the immune system slowly
but steadily declines. However, the infection kinetics
clearly consist of a two-phased process. The initial, acute
phase is characterized by an exceedingly high viral
replication rate accompanied by a massive loss of
memory CCR5
+CD4 T cells, particularly those that reside
within the gastrointestinal tract [5-9]. To a lesser extent,
macrophages and some dendritic cells that express CD4
and CCR5 are also affected. This is followed by a chronic
phase of variable but usually incomplete virus control,
which eventually develops into AIDS [10].
The frequent mutations of the replicating virus which
lead to incredible genomic heterogeneity impose an
enormous challenge for the design of an effective
vaccine. Perhaps more important in this context is the
ability of the virus to specifically target immune cells,
thereby increasingly breaking down the immune system
itself and inevitably leading to the development of AIDS.
Major recent advances
Back to the drawing board
It is not certain why the STEP trial failed, and why it even
increased the risk of HIV infection in those individuals
with pre-existing Ad-5-specific immunity. One possibi-
lity is that the expansion of Ad-5-specific CD4 memory
T cells could have created a permissive environment for
HIV infection [11]. Nevertheless, two recent studies
could not confirm a correlation between the numbers of
expanded Ad-5-specific T cells and an increased risk of
HIV infection in vaccinees with pre-existing Ad-5
immunity [12,13]. This suggests that other flaws under-
mined the success of the Ad-5/HIV vaccination strategy
and that new concepts need to be considered in order to
reach the finish line of successful vaccination.
Several studies have demonstrated that CD8
+ cytotoxic
T cell (CTL) responses play a crucial role in the initial
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[10,14-16]. In primary infections, a potent anti-HIV or
SIV specific CTL response is detected at a time when a
humoral response is weak or nonexistent, suggesting that
CD8
+ effector cells are key controllers of early viremia
[15,16]. Nevertheless, SIV-macaque models demon-
strated that measuring cellular immune responses to an
SIV vaccine, using in vitro assays on blood samples, does
not faithfully predict the efficacy of the vaccine. Low
levels of protection against SIV were observed in the face
of rather vigorous vaccine-induced immune responses
[17]. Also, live, attenuated SIV infection provided potent
protection against wild-type SIV, whereas only weak anti-
SIV immune responses were measured in vitro [18,19],
suggesting that vaccine-induced protection against HIV/
SIV might be critically dependent on localized, likely
mucosal-specific immune responses in vivo.
Consistent with the importance of the local response,
and further underscoring the central, early contribution
of CD8 T cells, are the results from nonhuman primates
demonstrating that depletion of CD8 T cells in vivo
resulted in enhanced AIDS viral replication during the
acute phase, increased loss of CCR5
+CD45RA
-CD4
T cells in the intestine, reduced humoral responses and,
ultimately, in an accelerated lethal outcome of the
disease in the infected monkeys [20-26].
The efficacy of virus-specific CD8 CTLs to control viral
replication and/or prevent AIDS led to the concept that
an effective vaccine should lead to the induction of a
strong and early viral-specific CD8 immune response
that, although unable to provide sterilizing protection,
ought to be able to control the viral load and delay or
prevent the onset of disease, as well as reduce the
potential for secondary transmission.
A major step forward: providing proof of concept
Unlike naïve T lymphocytes and central memory T cells
(TCMs), effector memory T cells (TEMs) have the ability to
reside long-term in non-lymphoid tissues, such as the gut
mucosa, and to provide immediate effector function,
without the pre-requisite of an initial proliferation step
[27]. This suggests that the generation of vaccine-induced
mucosal HIV-specific TEMs might provide front-line
protection to prevent the initial early phase of HIV
infection.
An important recent study by Hansen et al. [28] provides
direct support for this new paradigm. They demonstrated
that Rhesus macaques inoculated with rhesus cytome-
galovirus (RhCMV) vectors containing an SIV Gag, Rev-
Tat-Nef fusion protein, and Env were protected from
progressive wild-type SIV infection after repeated
limiting-dose intrarectal challenges. Moreover, the pro-
tected animals that were repeatedly infected via the
mucosal route showed no evidence of systemic infection
months later, suggesting that the infection was contained
locally, well before extensive viral replication or systemic
spreading of the virus. Interestingly, and in contrast to
the CMV vector-based protection that generated a high
frequency of SIV-specific TEMs, an Ad-5-boost vaccine
regimen, using the same limiting-dose intrarectal chal-
lenge protocol, instead induced a strong TCM-biased
immune response that did not provide protection
against SIV challenge.
Future directions
Turning the spotlight on TEMs as the mucosal
frontline defenders
Earlier SIV/macaque model studies also showed that
partial successful SIV protection was reached when
immunization was performed via the intranasal or oral
route [29,30], further stressing the issue that the
induction of mucosal immunity might be key for a
successful HIV/AIDS vaccination strategy. Most HIV
infections are acquired across a mucosal barrier, and
the mucosal immune system forms the main HIV
reservoir, the most important target for HIV replication,
and it endures the major early T cell losses [5,6,8]. The
depletion of mucosal T cell responses is probably the
result of direct infection of T cells and immune
exhaustion due not only to chronic activation by HIV,
but also to activation by intestinal bacteria. The rapid
and severe depletion of mucosal CCR5
+CD4 memory
T cells [5,6,8] results in a considerable translocation of
bacteria across the mucosal barrier [31]. Especially
critical is the loss of Th17 CD4 memory cells, a major
contributor to impaired barrier function [32]. Together
these processes contribute to the induction of chronic
systemic immune activation and T cell exhaustion.
In order to generate protective immunity, future HIV
vaccines will probably have to include the induction of
viral-specific TEM populations at relevant mucosal entry
surfaces as one of the absolute goals. A successful
protective immune response will need to be able to
sense a low dose of viral epitopes endogenously
produced by naturally infected cells, and to eliminate
those infected cells before extensive viral replication and
the loss of mucosal CD4 memory T cells occurs. This may
require specific immunization strategies other than
systemic immunization, and the development of more
accurate assays to distinguish mucosal HIV-specific T cell
responses from those of peripheral cells. But most of all,
we need to understand and identify the mechanisms and
factors that can direct vaccine-induced differentiation
and maintenance of highly effective and long-lived
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defense and destroy the pathogen before it gets a chance
to destroy its host.
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